Pretreatment with Dexamethasone Increases Antitumor Activity of Carboplatin and Gemcitabine in Mice Bearing Human Cancer Xenografts: In Vivo Activity, Pharmacokinetics, and Clinical Implications for Cancer Chemotherapy

Clinical Cancer Research

Volumn 10, Issue 5, 2004, Pages 1633-1644

  Wang, Hui ^a,c   Li, Mao ^a   Rinehart, John J ^b,c   Zhang, Ruiwen ^a,c  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; GEMCITABINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENTIATION; DRUG UPTAKE; GLIOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BREAST NEOPLASMS; CARBOPLATIN; COLONIC NEOPLASMS; DEOXYCYTIDINE; DEXAMETHASONE; DRUG SYNERGISM; GLIOMA; HALF-LIFE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 1842428890     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0829-3     Document Type: Article

References (53)

1. Demetri, G. D., and Anderson, K. C. Bone marrow failure. In: Clinical Oncology, pp. 443-456. New York: Churchill Livingstone, 1995.
2. Mackal, C. L. T-cell immunodeficiency following cytotoxic antine-oplastic therapy: a review. Stem Cells, 18: 10-18, 2000.
3. Griffin, J. Hematopoietic growth factors. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Cancer Principles and Practice of Oncology, 5th Ed., p. 2639-2657. Philadelphia: Lippincott-Raven, 1997.
4. Joyce, R., and Chervenick, P. Corticosteroid effect on granulopoiesis in mice after cyclophosphamide. J. Clin. Investig., 60: 277-283, 1977.
5. Kriegler, A., Bernardo, D., and Verschoor, S. Protection of murine bone marrow by dexamethasone during cytotoxic chemotherapy. Blood, 83: 65-71, 1994.
6. Rinehart, J., Delamater, E., and Keville, L. Corticosteroid modulation of interleukin-1 hematopoietic effects and toxicity in a murine system. Blood, 84: 1457-1463, 1994.
7. Rinehart, J., Keville, L., and Measel, J. Corticosteroid alteration of carboplatin-induced hematopoietic toxicity in a murine model. Blood, 86: 4493-4499, 1995.
8. Rinehart, J. J., and Keville, L. Corticosteroid alteration of carboplatin induced hematopoietic toxicity: comparison of efficacy in normal and hematopoietically impaired tumor bearing mice. Cancer Radiopharm., 2: 101-109, 1997.
9. Aman, M. J., Keller, U., and Derigs, G. Regulation of cytokine expression by interferon-α in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-a receptor antagonist. Blood, 84: 4142-4150, 1994.
10. Chudgar, U. H., Rundus, C. H., and Peterson, V. M. Recombinant human interleukin-1 receptor antagonist protects early myeloid progenitors in a murine model of cyclophosphamide-induced myelotoxicity. Blood, 85: 2393-2401, 1995.
11. Cashman, J. D., Eaves, A. C., and Raines, E. W. Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. I. Stimulatory role of a variety of mesenchymal cell activators and inhibitory role of TGF-β. Blood, 75: 96-101, 1990.
12. Futami, H., Jansen, R., and MacPhee, M. Chemoprotective effects of recombinant human IL-1α in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy. J. Immunol., 145: 4121-4130, 1990.
13. Dunlop, D., Wright, E., and Lorimore, S. Demonstration of stem cell inhibition and myeloprotective effects of SCI-rhMIP-Iα in vivo. Blood, 79: 2221-2225, 1992.
14. 2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin. J. Exp. Med., 180: 1047-1057, 1994.
15. Rinehart, J., Keville, L., Neidhart, J., Wong, L., DiNunno, L., Kinney, P., Aberle, M., Tadlock, L., and Cloud, G. Hematopoietic protection by dexamethasone of granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with carboplatin and ifosfamide. Am. J. Clin. Oncol., 26: 448-458, 2003.
16. Vadhan-Raj, S., Broxmeyer, H., and Hittelman, W. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J. Clin. Oncol., 10: 1266-1277, 1992.
17. Broxmeyer, H., Benningre, L., and Patel, S. Kinetic response of human marrow myeloid progenitor cells to in vivo treatment of patients with granulocyte colony-stimulating factor is different from the response to treatment with granulocyte-macrophage colony-stimulating factor. Exp. Hematol., 22: 100-102, 1994.
18. Janik, J., Miller, L., and Smith, J., II. Prechemotherapy granulocyte-macrophage colony stimulating factor (GM-CSF) prevents topotecan-induced neutropenia. Proc. Am. Soc. Clin. Oncol., 12: 1507, 1993.
19. Aglietta, M., Monzeglio, C., and Pasquino, P. Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs. Cancer (Phila.), 72: 2970-2973, 1993.
20. Betticher, D., Anderson, H., and Ranson, M. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomized Phase II study. Br. J. Cancer, 72: 1551-1555, 1995.
21. Gorman, A. M., Hirt, U. A., Orrenius, S., and Ceccatelli, S. Dexamethasone pre-treatment interferes with apoptotic death in glioma cells. Neuroscience, 96: 417-425, 2000.
22. Teicher, B. A., Herman, T. S., Holden, S. A., Wang, Y. Y., Pfeffer, M. R., Crawford, J. W., and Frei, E., III. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science (Wash. DC), 247: 1457-1461, 1990.
23. Kristjansen, P. E., Boucher, Y., and Jain, R. K. Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft. Cancer Res., 53: 4764-4766, 1993.
24. Rofstad, E. K., Tunheim, S. H., Mathiesen, B., Graff, B. A., Halsor, E. F., Nilsen, K., and Galappathi, K. Pulmonary and lymph node metastasis is associated with primary tumor interstitial fluid pressure in human melanoma xenografts. Cancer Res., 62: 661-664, 2002.
25. Matsukado, K., Nakano, S., Bartus, R. T., and Black, K. L. Steroids decrease uptake of carboplatin in rat gliomas: uptake improved by intracarotid infusion of bradykinin analog, RMP-7. J. Neurooncol., 34: 131-138, 1997.
26. Wang, H., Cai, Q., Zeng, X., Yu, D., Agrawal, S., and Zhang, R. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to RIα subunit of protein kinase A after oral administration. Proc. Natl. Acad. Sci. USA, 96: 13989-13994, 1999.
27. Wang, H., Nan, L., Yu, D., Agrawal, S., and Zhang, R. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin. Cancer Res., 7: 3613-3624, 2001.
28. Prasad, G., Wang, H., Agrawal, S., and Zhang, R. Antisense oligonucleotides targeted to MDM2 oncogene as a novel approach to the treatment of glioblastoma multiforme. Anticancer Res., 22: 107-116, 2002.
29. Wang, H., Nan, L., Yu, D., Lindsey, J. R., Agrawal, S., and Zhang, R. Antitumor efficacy of a novel antisense anti-mdm2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms. Mol. Med., 8: 184-198, 2002.
30. Zhang, R., Lu, Z., Liu, T., Soong, S-j., and Diasio, R. B. Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy. Cancer Res., 53: 2816-2822, 1993.
31. Bullen, W. W., Andress, L. D., Chang, T., Whitfield, L. R., Welch, M. L., and Newman, R. A. A high-performance liquid chromatographic assay for CI-973, a new anticancer platinum diamine complex, in human plasma and urine ultrafiltrates. Cancer Chemother. Pharmacol., 30: 193-198, 1992.
32. Zhang, R., Diasio, R. B., Lu, Z., Liu, T., Jiang, Z., Galbraith, W. M., and Agrawal, S., Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem. Pharmacol., 49: 929-939, 1995.
33. Wang, H., Li, M., Dubuisson, J., Scachinger, V., Haslinger, M., Rinehart, J. J., and Zhang, R. Dexamethasone as a chemoprotectant in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine. Proc. Am. Assoc. Cancer Res., 44: 392, 2003.
34. Braunschweiger, P. G., Ting, H. L., and Schiffer, L. M. Correlation between glucocorticoid receptor content and the antiproliferative effect of dexamethasone in experimental solid tumors. Cancer Res., 43: 4757-4761, 1983.
35. Braunschweiger, P. G., Ting, H. L., and Schiffer, L. M. Receptor-mediated antiproliferative effects of corticosteroids in Lewis lung tumors. Eur. J. Cancer Clin. Oncol., 20: 427-433, 1984.
36. Nishimura, K., Nonomura, N., Satoh, E., Harada, Y., Nakayama, M., Tokizane, T., Fukui, T., Ono, Y., Inoue, H., Shin, M., Tsujimoto, Y., Takayama, H., Aozasa, K., and Okuyama, A. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J. Natl. Cancer Inst. (Bethesda), 93: 1739-1746, 2001.
37. Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A., and Karin, M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science (Wash. DC), 270: 286-290, 1995.
38. Berrebi, D., Bruscoli, S., Cohen, N., Foussat, A., Migliorati, G., Bouchet-Delbos, L., Maillot, M. C., Portier, A., Couderc, J., Galanaud, P., Peuchmaur, M., Riccardi, C., and Emilie, D. Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10. Blood, 101: 729-738, 2003.
39. Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., and Baldwin, A. S., Jr. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science (Wash. DC), 281: 1680-1683, 1998.
40. Carmeliet, P., and Jain, R. K. Angiogenesis in cancer and other diseases. Nature (Lond.), 407: 249-257, 2000.
41. Braunschweiger, P. G., and Schiffer, L. M. Effect of dexamethasone on vascular function in RIF-1 tumors. Cancer Res., 46: 3299-3303, 1986.
42. Jain, R. K. Transport of molecules in the tumor interstitium: a review. Cancer Res., 47: 3039-3051, 1987.
43. Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., and McDonald, D. M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol., 156: 1363-1380, 2000.
44. Kerbel, R., and Folkman, J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer, 2: 727-739, 2002.
45. Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med., 7: 987-989, 2001.
46. Ono, M., Torisu, H., Fukushi, J., Nishie, A. and Kuwano, M. Biological implications of macrophage infiltration in human tumor angiogenesis. Cancer Chemother. Pharmacol., 43 (Suppl.): S69-S71, 1999.
47. Coussens, L. M., Werb, Z. Inflammation and cancer. Nature (Lond.), 420: 860-867, 2002.
48. Torisu, H., Ono, M., Kiryu, H., Furue, M., Ohmoto, Y., Nakayama, J., Nishioka, Y., Sone, S., and Kuwano, M. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFα and IL-1α. Int. J. Cancer, 85: 182-188, 2000.
49. Barbera-Guillem, E., Nyhus, J. K., Wolford, C. C., Friece, C. R., and Sampsel, J. W. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res., 62: 7042-7049, 2002.
50. Underwood, J. L., Murphy, C. G., Chen, J., Franse-Carman, L., Wood, I., Epstein, D. L., and Alvarado, J. A. Glucocorticoids regulate transendothelial fluid flow resistance and formation of intercellular junctions. Am. J. Physiol., 277: C330-C342, 1999.
51. Yamamoto, Y., and Gaynor, R. B. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J. Clin. Investig., 107: 135-142, 2001.
52. 3-mediated antitumor activity with dexamethasone. J. Natl. Cancer Inst. (Bethesda), 90: 134-141, 1998.
53. 3 with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. Clin. Cancer Res., 7: 4164-4173, 2001.